The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues

Neuropsychopharmacology

Volumn 33, Issue 6, 2008, Pages 1402-1412

  Fletcher, Paul J ^a,b   Rizos, Zoë ^a   Sinyard, Judy ^a   Tampakeras, Maria ^a   Higgins, Guy A ^c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NPS Pharmaceuticals   (Canada)

Author keywords

5 HT2C receptor; Cocaine self administration; Contextual cues; Reinstatement; Ro60 0175; Stress

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; COCAINE; YOHIMBINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR; ETHYLAMINE; INDOLE DERIVATIVE; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANIMAL BEHAVIOR; ASSOCIATION; DRUG EFFECT; DRUG INTERACTION; INSTRUMENTAL CONDITIONING; REINFORCEMENT; SPRAGUE DAWLEY RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; COCAINE; CONDITIONING, OPERANT; CUES; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHYLAMINES; EXTINCTION, PSYCHOLOGICAL; INDOLES; MALE; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SEROTONIN AGONISTS; YOHIMBINE;

EID: 42049096106     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301509     Document Type: Article

References (67)

1. Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD et al (2006). Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 116: 3229-3239.
2. Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M (1995). Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 34: 1635-1645.
3. Berg KA, Stout BD, Maayani S, Clarke WP (2001). Differences in rapid desensitization of 5-hydroxytryptamine2A and 5- hydroxytryptamine2C receptor-mediated phospholipase C activation. J Pharmacol Exp Ther 299: 593-602.
4. Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y (2005). Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 526: 36-50.
5. Bossert JM, Gray SM, Lu L, Shaham Y (2006). Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking. Neuropsychopharmacology 31: 2197-2209.
6. Bossert JM, Liu SY, Lu L, Shaham Y (2004). A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking. J Neurosci 24: 10726-10730.
7. Bremner JD, Krystal JH, Southwick SM, Charney DS (1996a). Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 23: 28-38.
8. Bremner JD, Krystal JH, Southwick SM, Charney DS (1996b). Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 23: 39-51.
9. 2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6: 1971-1985.
10. Burmeister JJ, Lungren EM, Kirschner KF, Neisewander JL (2004). Differential roles of 5-HT receptor subtypes in cue and cocaine reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 29: 660-668.
11. Callahan PM, Appel JB, Cunningham KA (1991). Dopamine D1 and D2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine. Psychopharmacology (Berl) 103: 50-55.
12. Capriles N, Rodaros D, Sorge RE, Stewart J (2003). A role for the prefrontal cortex in stress- and cocaine-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) 168: 66-74.
13. Charney DS, Woods SW, Goodman WK, Heninger GR (1987). Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144: 1030-1036.
14. 2C receptor protein in the rat CNS. Neuropharmacology 39: 123-132.
15. Crombag HS, Grimm JW, Shaham Y (2002). Effect of dopamine receptor antagonists on renewal of cocaine seeking by reexposure to drug-associated contextual cues. Neuropsychopharmacology 27: 1006-1015.
16. Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E (2006). Central serotonin2C receptor: from physiology to pathology. Curr Top Med Chem 6: 1909-1925.
17. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999). SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38: 1195-1205.
18. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (2000a). Biochemical and electrophysiological evidence that Ro 60-0175 inhibits mesolimbic dopaminergic function through serotonin2C receptors. Brain Res 865: 85-90.
19. Di Matteo V, Di Mascio M, Di Giovanni G, Esposito E (2000b). Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2C receptors. Psychopharmacology (Berl) 150: 45-51.
20. Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet MF (1997). Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384: 233-247.
21. Erb S, Salmaso N, Rodaros D, Stewart J (2001). A role for the CRF-containing pathway from central nucleus of the amygdala to bed nucleus of the stria terminalis in the stress-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) 158: 360-365.
22. Filip M, Bubar MJ, Cunningham KA (2004). Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J Pharmacol Exp Ther 310: 1246-1254.
23. Filip M, Cunningham KA (2003). Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin2C (5-HT2C) receptors in rat prefrontal cortex. J Pharmacol Exp Ther 306: 734-743.
24. Fletcher PJ, Chintoh AF, Sinyard J, Higgins GA (2004). Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Neuropsychopharmacology 29: 308-318.
25. Fletcher PJ, Grottick AJ, Higgins GA (2002). Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT2C receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27: 576-586.
26. Fone KC, Austin RH, Topham IA, Kennett GA, Punhani T (1998). Effect of chronic m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat. Br J Pharmacol 123: 1707-1715.
27. Fuchs RA, Evans KA, Ledford CC, Parker MP, Case JM, Mehta RH et al (2005). The role of the dorsomedial prefrontal cortex, basolateral amygdala, and dorsal hippocampus in contextual reinstatement of cocaine seeking in rats. Neuropsychopharmacology 30: 296-309.
28. Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN et al (2006). Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 51: 811-822.
29. Funk D, Li Z, Le AD (2006). Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: Relationship to the reinstatement of alcohol seeking. Neuroscience 138: 235-243.
30. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP et al (2000). Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36: 205-221.
31. Grottick AJ, Corrigall WA, Higgins GA (2001). Activation of 5-HT2C receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology (Berl) 157: 292-298.
32. Grottick AJ, Fletcher PJ, Higgins GA (2000). Studies to investigate the role of 5-HT2C receptors on cocaine- and food-maintained behavior. J Pharmacol Exp Ther 295: 1183-1191.
33. Hayashi A, Suzuki M, Sasamata M, Miyata K (2005). Agonist diversity in 5-HT2C receptor-mediated weight control in rats. Psychopharmacology (Berl) 178: 241-249.
34. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL et al (2002). Activation of central melanocortin pathways by fenfluramine. Science 297: 609-611.
35. Hewitt KN, Lee MD, Dourish CT, Clifton PG (2002). Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71: 691-700.
36. Higgins GA, Fletcher PJ (2003). Serotonin and drug reward: focus on 5-HT2C receptors. Eur J Pharmacol 480: 151-162.
37. Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB et al (2006). Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 51: 801-810.
38. Jandacek RJ (2005). APD-356 (Arena). Curr Opin Investig Drugs 6: 1051-1056.
39. Ji SP, Zhang Y, Van Cleemput J, Jiang W, Liao M, Li L et al (2006). Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse. Nat Med 12: 324-329.
40. Kelly PH, Iversen SD (1976). Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40: 45-56.
41. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V et al (1997). SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36: 609-620.
42. Le AD, Harding S, Juzytsch W, Funk D, Shaham Y (2005). Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology (Berl) 179: 366-373.
43. Lee B, Tiefenbacher S, Platt DM, Spealman RD (2004). Pharmacological blockade of alpha2-adrenoceptors induces reinstatement of cocaine-seeking behavior in squirrel monkeys. Neuropsychopharmacology 29: 686-693.
44. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ et al (1998). 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286: 913-924.
45. McFarland K, Davidge SB, Lapish CC, Kalivas PW (2004). Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci 24: 1551-1560.
46. McFarland K, Kalivas PW (2001). The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 21: 8655-8663.
47. Mendelson JH, Mello NK (1996). Management of cocaine abuse and dependence. N Engl J Med 334: 965-972.
48. Miller KJ (2005). Serotonin 5-HT2c receptor agonists: potential for the treatment of obesity. Mol Interv 5: 282-291.
49. Nilsson BM (2006). 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents. J Med Chem 49: 4023-4034.
50. O'Brien CP (1997). A range of research-based pharmacotherapies for addiction. Science 278: 66-70.
51. Pettit HO, Ettenberg A, Bloom FE, Koob GF (1984). Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology (Berl) 84: 167-173.
52. Pompeiano M, Palacios JM, Mengod G (1994). Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23: 163-178.
53. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF et al (1999). Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 128: 13-20.
54. Pozzi L, Acconcia S, Ceglia I, Invernizzi RW, Samanin R (2002). Stimulation of 5-hydroxytryptamine (5-HT2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem 82: 93-100.
55. Richardson NR, Roberts DC (1996). Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
56. Rowland NE (1994). Tolerance to the anorectic effect of dexfenfluramine in rats: role of serotonin, cholecystokinin, and neuropeptide Y. Physiol Behav 55: 201-207.
57. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168: 3-20.
58. Shepard JD, Bossert JM, Liu SY, Shaham Y (2004). The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry 55: 1082-1089.
59. Singewald N, Salchner P, Sharp T (2003). Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 53: 275-283.
60. Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH (2002). Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 51: 642-651.
61. Stout BD, Clarke WP, Berg KA (2002). Rapid desensitization of the serotonin2C receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 302: 957-962.
62. Tucci SA, Halford JC, Harrold JA, Kirkham TC (2006). Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr Med Chem 13: 2669-2680.
63. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka BK, Weinstein H et al (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
64. Vickers SP, Benwell KR, Porter RH, Bickerdike MJ, Kennett GA, Dourish CT (2000). Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 130: 1305-1314.
65. Volkow ND, Wise RA (2005). How can drug addiction help us understand obesity? Nat Neurosci 8: 555-560.
66. Wang Y, Joharchi N, Fletcher PJ, Sellers EM, Higgins GA (1995). Further studies to examine the nature of dexfenfluramine-induced suppression of heroin self-administration. Psychopharmacology (Berl) 120: 134-141.
67. 2C receptor-mediated hypolocomotion in rats. Pharmacol Biochem Behav 78: 683-689.